Reach your audience. Get results.

Rely on the experience, guidance, and superior media targeting of Business Wire for your global press release distribution.

Public Relations

Public Relations

Maximize the reach of your news with our press release distribution services and partnerships.

Investor Relations

Investor Relations

Reach and engage investors, shareholders, analysts, and media with our complete suite of IR services and tools.

Distribution and Analytics

Distribution & Analytics

Target your news, reach your audiences, and understand the impact of your press releases with our analytics reports.

News with Multimedia

Bristol-Myers Squibb and Tsinghua University Enter Strategic Partnership

PRINCETON, N.J. & BEIJING, China--()--Bristol-Myers Squibb Company (NYSE:BMY) and Tsinghua University of Beijing, China, today announced the formation of a multi-year strategic partnership.

Under the agreement, Bristol-Myers Squibb will fund research efforts at Tsinghua University’s School of Life Sciences to identify and validate novel targets in oncology and immunoscience. The collaboration will also focus on structural biology research, the science of mapping the 3D protein structure of biological molecular targets that could serve as the basis for future drug discovery projects.

“This is Bristol-Myers Squibb’s first discovery collaboration in China and is an example of the company’s deepening commitment to the country,” said Francis Cuss, M.D., senior vice president, Research. “We are delighted to be working with Tsinghua University, a world-renowned and highly esteemed research-based academic institution with expertise in target identification and structural biology that will support the discovery of new medicines to fight serious diseases in China and around the world.”

“On April 22, 1911, almost 101 years ago, Tsinghua University was founded. We have committed ourselves to working with the finest institutions and enterprises to jointly conduct cutting-edge research. In that spirit, Tsinghua University’s School of Life Sciences is building a strategic partnership with Bristol-Myers Squibb,” said Professor Kejun Kang, vice president of Tsinghua University. “I strongly believe that future cooperation between Tsinghua University and Bristol-Myers Squibb will bring about further-reaching consequences to both organizations and I wish every success in this cooperation.”

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

About Tsinghua University

Founded in 1911, Tsinghua University is a world-renowned university. With the motto of “Self-Discipline and Social Commitment” and the spirit of “Actions Speak Louder than Words,” Tsinghua University is dedicated to the well-being of Chinese society and to world development. For more information, please visit http://www.tsinghua.edu.cn.

Contacts

Bristol-Myers Squibb
Media:
Jennifer Fron Mauer (United States), 609-252-6579,
jennifer.mauer@bms.com;
Stella Ling, (China), +86-21-2321-8218,
stella.ling@bms.com
Investors:
John Elicker, 609-252-4611,
john.elicker@bms.com
or
Tsinghua University
Yi Jiang +86- 10-62796742, yijiang@biomed.tsinghua.edu.cn

Recent Stories

RSS feed for Bristol-Myers Squibb

Release Versions

Company Information Center

Bristol-Myers Squibb RSS feed for Bristol-Myers Squibb

NYSE:BMY

More News with Multimedia

Latest News

Bristol-Myers Squibb and Tsinghua University Enter Strategic Partnership

PRINCETON, N.J. & BEIJING, China--()--Bristol-Myers Squibb Company (NYSE:BMY) and Tsinghua University of Beijing, China, today announced the formation of a multi-year strategic partnership.

Under the agreement, Bristol-Myers Squibb will fund research efforts at Tsinghua University’s School of Life Sciences to identify and validate novel targets in oncology and immunoscience. The collaboration will also focus on structural biology research, the science of mapping the 3D protein structure of biological molecular targets that could serve as the basis for future drug discovery projects.

“This is Bristol-Myers Squibb’s first discovery collaboration in China and is an example of the company’s deepening commitment to the country,” said Francis Cuss, M.D., senior vice president, Research. “We are delighted to be working with Tsinghua University, a world-renowned and highly esteemed research-based academic institution with expertise in target identification and structural biology that will support the discovery of new medicines to fight serious diseases in China and around the world.”

“On April 22, 1911, almost 101 years ago, Tsinghua University was founded. We have committed ourselves to working with the finest institutions and enterprises to jointly conduct cutting-edge research. In that spirit, Tsinghua University’s School of Life Sciences is building a strategic partnership with Bristol-Myers Squibb,” said Professor Kejun Kang, vice president of Tsinghua University. “I strongly believe that future cooperation between Tsinghua University and Bristol-Myers Squibb will bring about further-reaching consequences to both organizations and I wish every success in this cooperation.”

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

About Tsinghua University

Founded in 1911, Tsinghua University is a world-renowned university. With the motto of “Self-Discipline and Social Commitment” and the spirit of “Actions Speak Louder than Words,” Tsinghua University is dedicated to the well-being of Chinese society and to world development. For more information, please visit http://www.tsinghua.edu.cn.

Contacts

Bristol-Myers Squibb
Media:
Jennifer Fron Mauer (United States), 609-252-6579,
jennifer.mauer@bms.com;
Stella Ling, (China), +86-21-2321-8218,
stella.ling@bms.com
Investors:
John Elicker, 609-252-4611,
john.elicker@bms.com
or
Tsinghua University
Yi Jiang +86- 10-62796742, yijiang@biomed.tsinghua.edu.cn

Recent Stories

RSS feed for Bristol-Myers Squibb

Release Versions

Company Information Center

Bristol-Myers Squibb RSS feed for Bristol-Myers Squibb

NYSE:BMY

All News